Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies
The incorporation of novel therapies, including checkpoint inhibitors and antibody‑drug conjugates, into the frontline setting, sequential approaches, and further individualized treatment intensity may address unmet clinical needs and improve outcomes in classical Hodgkin lymphoma.
Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Related signals
- Advanced Classical Hodgkin Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group.
- Overcoming PD‑1 Resistance in Relapsed/Refractory Hodgkin Lymphoma
- Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era
- Combination of Acimtamig and AlloNK Effective in R/R Classical Hodgkin Lymphoma
- Working towards harmonization of clinical trial reporting in Hodgkin lymphoma